Phase 1 Clinical Study of MWN110 Injection in Healthy Participants and Overweight or Obese Participants

This study is a multicenter, randomized, double‐blind, placebo‐controlled, single andmultiple ascending‐dose phase 1 clinical trial aimed at evaluating the safety,tolerability, PK, PD, and immunogenicity of MWN110 Injection in healthy participants andoverweight or obese participants.The study consists of two parts: Part 1, a single ascending dose (SAD) study in healthyparticipants with 8 dose cohorts; and Part 2, a multiple ascending dose (MAD) study inoverweight or obese participants with 3 dose cohorts, with a dosing frequency of onceweekly or once every 4 weeks.Approximately 103 participants will be enrolled. The primary endpoint is safety andtolerability, assessed by adverse events, vital signs, physical examination, laboratorytests, 12‐lead electrocardiogram, and ophthalmic examination. Secondary endpoints includesingle‐dose and multiple‐dose PK parameters, PD parameters (body weight, BMI, waistcircumference, muscle mass, body fat percentage, visceral fat, subcutaneous fat, bonemineral density), and immunogenicity (anti‐drug antibodies).